An inverse relationship between markers of fibrogenesis and collagen degradation in patients with or without alcoholic liver disease

American Journal of Gastroenterology

Volumn 102, Issue 4, 2007, Pages 773-779

  Koivisto, Heidi ^a   Hietala, Johanna ^a   Niemelä, Onni ^a,b  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b SEINÄJOKI CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; AMINO TERMINAL TYPE 3 COLLAGEN PROPEPTIDE; BETA CROSSLAPS PROTEIN; BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN; CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ALCOHOL LIVER DISEASE; ALCOHOLISM; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CALCULATION; CLINICAL FEATURE; COLLAGEN DEGRADATION; CONTROL GROUP; CONTROLLED STUDY; DISEASE MARKER; FIBRIN FORMATION; HISTOPATHOLOGY; HUMAN; INFLAMMATION; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LIVER DISEASES, ALCOHOLIC; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROCOLLAGEN; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 33947657452     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2006.01036.x     Document Type: Article

References (55)

1. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115:209-18.
2. Friedman SL. Liver fibrosis - from bench to bedside. J Clin Invest 2003;38(suppl 1):S38-53.
3. Lieber CS. Medical disorders of alcoholism. J Clin Invest 1995;333:1058-65.
4. Kamal SM, Turner B, He Q, et al. Progression of fibrosis in hepatitis C with and without schistosomiasis: Correlation with serum markers of fibrosis. Hepatology 2006;43:771-9.
5. McCullough AJ, Stassen WN, Wiesner RH, et al. Serumtype III procollagen peptide concentrations in severe chronic active hepatitis: Relationship to cirrhosis and disease activity. Hepatology 1987;7:49-54.
6. Niemelä O, Risteli L, Sotaniemi EA, et al. Aminoterminal propeptide of type III procollagen in serum in alcoholic liver disease. Gastroenterology 1983;85:254-9.
7. Torres-Salinas M, Pares A, Caballeria J, et al. Serum procollagen type III peptide as a marker of hepatic fibrogenesis in alcoholic hepatitis. Gastroenterology 1986;90:1241-6.
8. Niemelä O, Risteli J, Blake JE, et al. Markers of fibrogenesis and basement membrane formation in alcoholic liver disease. Relation to severity, presence of hepatitis, and alcohol intake. Gastroenterology 1990;98:1612-9.
9. Pemberton PW, Smith A, Warnes TW. Non-invasive monitoring of oxidant stress in alcoholic liver disease. Scand J Gastroenterol 2005;40:1102-8.
10. Rosman AS, Lieber CS. Diagnostic utility of laboratory tests in alcoholic liver disease. Clin Chem 1994;40:1641-51.
11. Nøjgaard C, Johansen JS, Christensen E, et al. Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease. J Hepatol 2003;39:179-86.
12. Teare JP, Sherman D, Greenfield SM, et al. Comparison of serumprocollagen III peptide concentrations and PGA index for assessment of hepatic fibrosis. Lancet 1993;342:895-8.
13. Trinchet JC, Hartmann DJ, Pateron D, et al. Serum type I collagen and N-terminal peptide of type III procollagen in patients with alcoholic liver disease: Relationship to liver histology. Alcohol Clin Exp Res 1992;16:342-6.
14. Okabe R, Nakatsuka K, Inaba M, et al. Clinical evaluation of the Elecsys beta-CrossLaps serum assay, a new assay for degradation products of type I collagen C-telopeptides. Clin Chem 2001;47:1410-4.
15. Reichel H, Roth HJ, Schmidt-Gayk H. Evaluation of serum beta-carboxy-terminal cross-linking telopeptide of type I collagen as marker of bone resorption in chronic hemodialysis patients. Nephron Clin Pract 2004;98:c112-8.
16. Orrego H, Israel Y, Blake JE, et al. Assessment of prognostic factors in alcoholic liver disease: Toward a global quantitative expression of severity. Hepatology 1983;3:896-905.
17. Orrego H, Blake JE, Blendis LM, et al. Prognosis of alcoholic cirrhosis in the presence and absence of alcoholic hepatitis. Gastroenterology 1987;92:208-14.
18. Room R, Babor T, Rehm J. Alcohol and public health. Lancet 2005;365:519-30.
19. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003;38:1449-57.
20. Callewaert N, Van Vlierberghe H, Van Hecke A, et al. Non-invasive diagnosis of liver cirrhosis using DNA sequencerbased total serumprotein glycomics. Nat Med 2004;10:429-34.
21. Ghany MG, Doo E. Assessment of liver fibrosis: Palpate, poke or pulse? Hepatology 2005;42:759-61.
22. Imbert-Bismut F, Ratziu V, Pieroni L, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: A prospective study. Lancet 2001;357:1069-75.
23. Maher JJ, McGuire RF. Extracellular matrix gene expression increases preferentially in rat lipocytes and sinusoidal endothelial cells during hepatic fibrosis in vivo. J Clin Invest 1990;86:1641-8.
24. Rojkind M, Giambrone MA, Biempica L. Collagen types in normal and cirrhotic liver. Gastroenterology 1979;76:710-9.
25. Garnero P, Ferreras M, Karsdal MA, et al. The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 2003;18:859-67.
26. Rosen HN, Moses AC, Garber J, et al. Serum CTX: A new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 2000;66:100-3.
27. Iredale JP. Cirrhosis:Newresearch provides a basis for rational and targeted treatments. J Clin Invest 2003;327:143-7.
28. Maruyama K, Feinman L, Fainsilber Z, et al. Mammalian collagenase increases in early alcoholic liver disease and decreases with cirrhosis. Life Sci 1982;30:1379-84.
29. Li J, Rosman AS, Leo MA, et al. Tissue inhibitor of metalloproteinase is increased in the serum of precirrhotic and cirrhotic alcoholic patients and can serve as a marker of fibrosis. Hepatology 1994;19:1418-23.
30. Crews FT, Bechara R, Brown LA, et al. Cytokines and alcohol. Alcohol Clin Exp Res 2006;30:720-30.
31. Hill DB, Marsano LS, McClain CJ. Increased plasma interleukin-8 concentrations in alcoholic hepatitis. Hepatology 1993;18:576-80.
32. Khoruts A, Stahnke L, McClain CJ, et al. Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholic patients. Hepatology 1991;13:267-76.
33. Latvala J, Hietala J, Koivisto H, et al. Immune responses to ethanol metabolites and cytokine profiles differentiate alcoholics with or without liver disease. Am J Gastroenterol 2005;100:1303-10.
34. McClain CJ, Cohen DA. Increased tumor necrosis factor production by monocytes in alcoholic hepatitis. Hepatology 1989;9:349-51.
35. Neuman MG, Brenner DA, Rehermann B, et al. Mechanisms of alcoholic liver disease: Cytokines. Alcohol Clin Exp Res 2001;25:251S-3S.
36. Fujimoto M, Uemura M, Nakatani Y, et al. Plasma endotoxin and serum cytokine levels in patients with alcoholic hepatitis: Relation to severity of liver disturbance. Alcohol Clin Exp Res 2000;24:48S-54S.
37. Hill DB, Marsano L, Cohen D, et al. Increased plasma interleukin-6 concentrations in alcoholic hepatitis. J Lab Clin Med 1992;119:547-52.
38. Rodríguez-Rodríguez E, González-Reimers E, Santolaria-Fernández F, et al. Cytokine levels in acute alcoholic hepatitis: A sequential study. Drug Alcohol Depend 1995;39:23-7.
39. Bird GL, Sheron N, Goka AK, et al. Increased plasma tumor necrosis factor in severe alcoholic hepatitis. Ann Intern Med 1990;112:917-20.
40. Felver ME, Mezey E, McGuire M, et al. Plasma tumor necrosis factor alpha predicts decreased long-term survival in severe alcoholic hepatitis. Alcohol Clin Exp Res 1990;14:255-9.
41. Huang YS, Chan CY, Wu JC, et al. Serum levels of interleukin-8 in alcoholic liver disease: Relationship with disease stage, biochemical parameters and survival. J Hepatol 1996;24:377-84.
42. McClain C, Barve S, Joshi-Barve S, et al. Dysregulated cytokine metabolism, altered hepatic methionine metabolism and proteasome dysfunction in alcoholic liver disease. Alcohol Clin Exp Res 2005;29:180S-8S.
43. Swiatkowska-Stodulska R, Bakowska A, Drobinska-Jurowiecka A. Interleukin-8 in the blood serum of patients with alcoholic liver disease. Med Sci Monit 2006;12:CR215-20.
44. Colantoni A, Idilman R, De Maria N, et al. Hepatic apoptosis and proliferation in male and female rats fed alcohol: Role of cytokines. Alcohol Clin Exp Res 2003;27:1184-9.
45. Iimuro Y, Gallucci RM, Luster MI, et al. Antibodies to tumor necrosis factor alfa attenuate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat. Hepatology 1997;26:1530-7.
46. Yin M, Wheeler MD, Kono H, et al. Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice. Gastroenterology 1999;117:942-52.
47. Joshi-Barve S, Barve SS, Butt W, et al. Inhibition of proteasome function leads to NF-kappaB-independent IL-8 expression in human hepatocytes. Hepatology 2003;38:1178-87.
48. Streetz KL, Luedde T, Manns MP, et al. Interleukin 6 and liver regeneration. Gut 2000;47:309-12.
49. Taub R. Hepatoprotection via the IL-6/Stat3 pathway. J Clin Invest 2003;112:978-80.
50. Zimmers TA, McKillop IH, Pierce RH, et al. Massive liver growth in mice induced by systemic interleukin 6 administration. Hepatology 2003;38:326-34.
51. Chen WX, Li YM, Yu CH, et al. Quantitative analysis of transforming growth factor beta 1 mRNA in patients with alcoholic liver disease. World J Gastroenterol 2002;8:379-81.
52. Chakkalakal DA. Alcohol-induced bone loss and deficient bone repair. J Clin Invest 2005;29:2077-90.
53. Chen CC, Wang SS, Jeng FS, et al. Metabolic bone disease of liver cirrhosis: Is it parallel to the clinical severity of cirrhosis? J Gastroenterol Hepatol 1996;11:417-21.
54. Vignesh RC, Sitta DS, Jayasudha E, et al. Effect of ethanol on human osteosarcoma cell proliferation, differentiation and mineralization. Toxicology 2006;220:63-70.
55. Guañabens N, Parés A, Alvarez L, et al. Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis. J Bone Miner Res 1998;13:731-8.